四川成渝高速公路(00107.HK)向控股股東出售房地產項目 涉資18.6億人幣
四川成渝高速公路(00107.HK)公布,與控股股東四川交投地產訂立股權及相應股東借款轉讓協議,公司同意向四川交投地產出售待售股權,即仁壽置地的91%股權及待售貸款,現金總代價為不超過約18.58億元人民幣(下同);同時公司直接全資附屬成都蜀鴻向四川交投地產出售「鴻瑞國際廣場」的在建房地產項目,現金總代價為不超過約8,700萬元。
仁壽置地持有的相關資產主要包括在中國持作銷售用途/發展中/未來發展的物業,持有待售物業為中國四川省眉山市仁壽縣文林鎮城北新城北方王朝一期及2A期的未售出部分。於仁壽出售完成後,四川交投地產將持有仁壽置地100%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.